CRP and rheumatoid arthritis: In assessing a series of patients with RA in treatment with the anti-TNF-α monoclonal antibody infliximab for severe disease refractory to conventional DMARD therapy including methotrexate, we found positive correlations between markers of inflammation, in particular with C-reactive protein, and resistin levels [60].